Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1, Multicenter, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered FHD-286, as Monotherapy or Combination Therapy, in Subjects With Advanced Hematologic Malignancies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT04891757
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:36.725052+00:00
Published At
2025-07-10T00:00:00+00:00
Record Updated At
2025-07-10
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Advanced Hematologic Malignancy", "Relapsed Acute Myeloid Leukemia", "Refractory Acute Myeloid Leukemia", "Relapsed Myelodysplastic Syndromes", "Refractory Myelodysplastic Syndromes", "Relapsed Chronic Myelomonocytic Leukemia", "Refractory Chronic Myelomonocytic Leukemia"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-07-10"
protocolSection.identificationModule.nctId
"NCT04891757"
protocolSection.identificationModule.officialTitle
"A Phase 1, Multicenter, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered FHD-286, as Monotherapy or Combination Therapy, in Subjects With Advanced Hematologic Malignancies"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Advanced Hematologic Malignancy (protocolSection.conditionsModule.conditions)
  • Relapsed Acute Myeloid Leukemia (protocolSection.conditionsModule.conditions)
  • Refractory Acute Myeloid Leukemia (protocolSection.conditionsModule.conditions)
  • Relapsed Myelodysplastic Syndromes (protocolSection.conditionsModule.conditions)
  • Refractory Myelodysplastic Syndromes (protocolSection.conditionsModule.conditions)
  • Relapsed Chronic Myelomonocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Refractory Chronic Myelomonocytic Leukemia (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.